Markets:

Overview

News

Currencies

International

Treasuries

Organon & Co. Common Stock (NY:OGN)

8.190 +0.120 (+1.49%)

Official Closing Price Updated: 7:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

3 High-Yield Dividend ETFs to Buy to Generate Passive Income ↗

July 06, 2024

These exchange-traded funds should keep the income flowing in regularly.

Via The Motley Fool

Topics ETFs

High Dividend 50: Organon & Co. ↗

June 27, 2024

Organon & Co.’s current annual dividend is $1.12 per share. At around $20 per share, Organon stock has a high yield of 5.4%.

Via Talk Markets

Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now ↗

June 26, 2024

Uncover three top value stocks to buy with robust fundamentals for stable long-term growth amid turbulence.

Via InvestorPlace

3 Stocks With Mouthwatering Dividends You Can Buy Right Now ↗

June 08, 2024

These stocks offer great dividends and more.

Via The Motley Fool

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

May 24, 2024

From Organon & Co.

Via Business Wire

Thursday Is Your Last Chance To Buy Organon Before The Dividend Payout ↗

February 20, 2024

Via Benzinga

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields ↗

May 10, 2024

Via Benzinga

Organon Announces Pricing of $1.0 Billion Senior Notes Offering

May 07, 2024

From Organon & Co.

Via Business Wire

Organon Announces Proposed $1.0 Billion Senior Notes Offering

May 07, 2024

From Organon & Co.

Via Business Wire

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Organon Beats On Q1, Women's Health Leads the Charge ↗

May 02, 2024

Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.

Via Benzinga

OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

OGN stock results show that Organon beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Organon Reports Results for the First Quarter Ended March 31, 2024

May 02, 2024

From Organon & Co.

Via Business Wire

7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024 ↗

May 01, 2024

While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing.

Via InvestorPlace

3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 ↗

May 01, 2024

Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.

Via InvestorPlace

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

April 08, 2024

From Organon & Co.

Via Business Wire

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

April 08, 2024

From Organon & Co.

Via Business Wire

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields ↗

March 13, 2024

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally ↗

March 07, 2024

Here are three top stock picks for rally have their grip in travel, packaged foods, meats and pharmaceuticals.

Via InvestorPlace

5 Value Stocks In The Healthcare Sector ↗

March 04, 2024

Via Benzinga

Drug Maker Organon Stock Scores Relative Strength Upgrade ↗

February 28, 2024

In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.

Via Investor's Business Daily

Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market ↗

February 26, 2024

Explore growth strategies of overlooked stocks with strong fundamentals in strategic investments and market expansion.

Via InvestorPlace

New York Attorney General Urges FDA Action On Widely Used Asthma Drug's Concerns Over Pediatric Safety ↗

February 26, 2024

The Attorney General of New York, Letitia James, has called on the FDA to address safety risks associated with the widely used asthma and allergy medicine Singulair (montelukast).

Via Benzinga

Don't Overlook These Low-Risk High-Dividend Yielding Stocks ↗

February 24, 2024

Given the rally in the S&P 500 and the Nasdaq over the last year, it may be wise to consider stocks that should be less volatile during market corrections. Even better is when stocks have dividend...

Via Talk Markets

Topics Stocks

First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks ↗

February 21, 2024

Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women's Health aims to promote innovative solutions.

Via Benzinga

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

February 20, 2024

From Organon & Co.

Via Business Wire

Why Is Women Health-Focused Organon Stock Trading Higher On Thursday? ↗

February 15, 2024

Organon exceeds Q4 2023 revenue expectations, reaching $1.6 billion. Women's Health thrives with 7% revenue increase, driven by Follistim AQ's 63% growth. Biosimilar revenue surges by 49%.

Via Benzinga

Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday ↗

February 15, 2024

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

Via Benzinga

Topics Stocks

Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 15, 2024

Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings.

Via Benzinga

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 15, 2024

From Organon & Co.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.